In situ gelation of rhEGF-containing liquid crystalline precursor with good cargo stability and system mechanical properties: a novel delivery system for chronic wounds treatment

2019 ◽  
Vol 7 (3) ◽  
pp. 995-1010 ◽  
Author(s):  
Chan Zhou ◽  
Zhengwei Huang ◽  
Ying Huang ◽  
Bei Wang ◽  
Peipei Yang ◽  
...  
Keyword(s):  
Mechanical Properties ◽  
Growth Factor ◽  
Delivery System ◽  
Liquid Crystalline ◽  
Chronic Wounds ◽  
Chronic Wound ◽  
Wound Treatment ◽  
In Situ Gelation ◽  
Epidermal Growth

The objective of this study was to develop a novel delivery system for recombinant human epidermal growth factor (rhEGF) for chronic wound treatment.

scholarly journals Effect of moist dressing, collagen sheet dressing and epidermal growth factor in healing of chronic wounds

2017 ◽  
Vol 4 (8) ◽  
pp. 2594
Author(s):  
Sheelchandra Jain ◽  
Darshana S. Tote ◽  
Gaurav Kolte ◽  
Suhas Jajoo ◽  
Sachin Tote
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Chronic Wounds ◽  
Chronic Wound ◽  
Cost Effective ◽  
Functional Results ◽  
Treated Group ◽  
Controlled Study ◽  
Collagen Group ◽  
Epidermal Growth

Background: Surgical literature is full of innumerable solutions to the problems of wound healing and it speaks of itself that the problem is not so simple and straight forward to tackle with. The aim of the present study was to compare three modalities moist saline dressing, collagen sheet dressing and epidermal growth factor in early epithelization and healing of chronic wounds. to study the effect of various dressing modalities on epithelization of chronic wound in terms of time required for healing and the quality of scar it forms, the functional results both early and late, post-healing morbidity and complications and the practicality and the cost involved in using these modalities.Methods: Prospective randomized controlled study. Study including chronic wound cases admit to AVBRH Sawangi over period of 3 years.Results: Reduction in size of wound by 70-100% was found highest in Epigrof group. In Epigrof treated group 88% of wounds healed within 3 weeks while 80% in collagen group and 56% in moist dressing group it. Collagen dressing is the most cost effective of the three whereas Epigrof was most costly due to the initial cost of purchase. The scar quality was satisfactory in 19 of Epigrof group and 17 of the collagen sheet group and 15 of the moist dressing group.Conclusions: Epidermal growth factor is superior in epithelization, collagen is the next best local applicant, but collagen sheet is more cost effective than Epigrof and non-adherent dressings.

scholarly journals Cellular Response to Vitamin C-Enriched Chitosan/Agarose Film with Potential Application as Artificial Skin Substitute for Chronic Wound Treatment

Cells ◽  
2020 ◽  
Vol 9 (5) ◽  
pp. 1185 ◽  
Author(s):  
Vladyslav Vivcharenko ◽  
Michal Wojcik ◽  
Agata Przekora
Keyword(s):  
Growth Factor ◽  
Vitamin C ◽  
Human Skin ◽  
Cellular Response ◽  
Chronic Wounds ◽  
Chronic Wound ◽  
Artificial Skin ◽  
Skin Substitute ◽  
Wound Treatment ◽  
Human Skin Fibroblasts

The treatment of chronic wounds is still a meaningful challenge to physicians. The aim of this work was to produce vitamin C-enriched chitosan/agarose (CHN/A) film that could serve as potential artificial skin substitute for chronic wound treatment. The biomaterial was fabricated by a newly developed and simplified method via mixing acidic chitosan solution with alkaline agarose solution that allowed to obtain slightly acidic pH (5.97) of the resultant material, which is known to support skin regeneration. Vitamin C was immobilized within the matrix of the film by entrapment method during production process. Produced films (CHN/A and CHN/A + vit C) were subjected to comprehensive evaluation of cellular response with the use of human skin fibroblasts, epidermal keratinocytes, and macrophages. It was demonstrated that novel biomaterials support adhesion and growth of human skin fibroblasts and keratinocytes, have ability to slightly reduce transforming growth factor-beta 1 (TGF-β1) (known to be present at augmented levels in the epidermis of chronic wounds), and increase platelet-derived growth factor-BB (PDGF-BB) secretion by the cells. Nevertheless, addition of vitamin C to the biomaterial formulation does not significantly improve its biological properties due to burst vitamin release profile. Obtained results clearly demonstrated that produced CHN/A film has great potential to be used as cellular dermal, epidermal, or dermo-epidermal graft pre-seeded with human skin cells for chronic wound treatment.

scholarly journals Synergistic effects of hyaluronate – epidermal growth factor conjugate patch on chronic wound healing

2018 ◽  
Vol 6 (5) ◽  
pp. 1020-1030 ◽  
Author(s):  
Yun Seop Kim ◽  
Dong Kyung Sung ◽  
Won Ho Kong ◽  
Hyemin Kim ◽  
Sei Kwang Hahn
Keyword(s):  
Wound Healing ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Chronic Wounds ◽  
Chronic Wound ◽  
Synergistic Effects ◽  
Topical Delivery ◽  
Epidermal Growth

A HA–EGF conjugate patch was developed for the treatment of diabetic chronic wounds with advantages such as facilitating topical delivery and interaction with dual receptors, and alleviating the degradation of EGF.

Apoptosis in human cultured trophoblasts is enhanced by hypoxia and diminished by epidermal growth factor

2000 ◽  
Vol 278 (5) ◽  
pp. C982-C988 ◽  
Author(s):  
Roni Levy ◽  
Steven D. Smith ◽  
Kala Chandler ◽  
Yoel Sadovsky ◽  
D. Michael Nelson
Keyword(s):  
Cell Differentiation ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Fetal Growth ◽  
Fetal Growth Restriction ◽  
Caspase Inhibitor ◽  
Trophoblast Differentiation ◽  
Epidermal Growth ◽  
Induced Apoptosis

Preeclampsia and fetal growth restriction are associated with placental hypoperfusion and villous hypoxia. The villous response to this environment includes diminished trophoblast differentiation and enhanced apoptosis. We tested the hypothesis that hypoxia induces apoptosis in cultured trophoblasts, and that epidermal growth factor (EGF), an enhancer of trophoblast differentiation, diminishes hypoxia-induced apoptosis. Trophoblasts isolated from placentas of term-uncomplicated human pregnancies were cultured up to 72 h in standard ([Formula: see text]= 120 mmHg) or hypoxic ([Formula: see text] < 15 mmHg) conditions. Exposure to hypoxia for 24 h markedly enhanced trophoblast apoptosis as determined by DNA laddering, internucleosomal in situ DNA fragmentation, and histomorphology, as well as by the reversibility of the apoptotic process with a caspase inhibitor. Apoptosis was accompanied by increased expression of p53 and Bax and decreased expression of Bcl-2. Addition of EGF to cultured trophoblasts or exposure of more differentiated trophoblasts to hypoxia significantly lowered the level of apoptosis. We conclude that hypoxia enhances apoptosis in cultured trophoblasts by a mechanism that involves an increase in p53 and Bax expression. EGF and enhancement of cell differentiation protect against hypoxic-induced apoptosis.

scholarly journals A method for pet mechanical properties enhancement

2019 ◽  
Vol 10 (8) ◽  
pp. 1725
Author(s):  
Raffaella Aversa ◽  
Relly Victoria Virgil Petrescu ◽  
Antonio Apicella ◽  
Florian Ion Tiberiu Petrescu
Keyword(s):  
Mechanical Properties ◽  
Liquid Crystalline ◽  
Liquid Crystalline Polymers ◽  
Molecular Structures ◽  
Reactive Blending ◽  
Scanning Calorimetry ◽  
Shear Transfer ◽  
Crystalline Polymers ◽  
Reactive Compatibilizer

A method for PET mechanical properties enhancement by reactive blending with HBA/HNA Liquid Crystalline Polymers for in situ highly fibrillar composites preparation is presented. LCP/PET blends were reactively extruded in presence of Pyromellitic Di-Anhydride (PMDA) and then characterized by Differential Scanning Calorimetry, Thermally Stimulated Currents and tensile mechanical properties. Moderate amounts of LCP in the PET (0.5 and 5%) and small amounts of thermo-active and reactive compatibilizer in the blend (0.3%) were found to significantly improve LCP melt dispersion, melts shear transfer and LCP fibril formation and adhesion. An unexpected improvement was probably due to the presence of two distinct phases’ supra-molecular structures involving PET-LCP and PMDA.

Epidermal Growth Factor—Interactions with Normal and Malignant Urothelium: In Vivo and in Situ Studies

1987 ◽  
Vol 138 (5) ◽  
pp. 1329-1335 ◽  
Author(s):  
Edward M. Messing ◽  
Patricia Hanson ◽  
Peter Ulrich ◽  
Edrogen Erturk
Keyword(s):  
Growth Factor ◽  
Epidermal Growth Factor ◽  
In Situ Studies ◽  
Epidermal Growth ◽  
Factor Interactions

Increased Likelihood of Mastectomy in Human Epidermal Growth Factor Receptor 2-positive Ductal Carcinoma In Situ

2014 ◽  
Vol 80 (10) ◽  
pp. 936-939 ◽  
Author(s):  
Anna Weiss ◽  
Vivi Tran ◽  
Jennifer Baker ◽  
Hasteh Farnaz ◽  
Anne M. Wallace ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Growth Factor Receptor ◽  
Human Epidermal Growth Factor ◽  
Epidermal Growth

Patients with human epidermal growth factor receptor 2 (HER2neu)-positive breast invasive cancer are known to have larger, more aggressive tumors. Little research exists on the relationship between HER2neu status and extent of ductal carcinoma in situ (DCIS). A retrospective review of a single-institution database was performed for patients with DCIS between the years 2002 and 2011. A single blinded breast radiologist reviewed preoperative imaging. Pathology was reviewed for extent of DCIS. Primary outcome was mastectomy. Multivariate logistic regression was used to determine adjusted mastectomy risk. There were 166 cases, 34 HER2neu-positive. HER2neu receptor-positive patients had larger lesions on imaging: 4.0 versus 2.7 cm, by 2.9 versus 1.5 cm ( P = 0.0499 and 0.0182). HER2neu-positive patients with DCIS were more likely than HER2neu-negative to undergo mastectomy than lumpectomy (53 vs 28%, P = 0.006). Pathology revealed a trend toward larger lesions in HER2neu-positive patients (2.96 vs 2.22 cm, nonsignificant). Patients with HER2neu-positive disease were three times more likely to undergo mastectomy (odds ratio, 2.9; 95% confidence interval, 1.23 to 6.78). Patients with HER2neu-positive DCIS had greater extent of disease by imaging and were more likely to undergo mastectomy than HER2neu-negative. These findings will help surgeons counsel patients on surgical treatment.

Sign in / Sign up

Export Citation Format

Share Document